Results 271 to 280 of about 115,105 (360)

Treatment of morphea with hydroxychloroquine: A retrospective review of 84 patients at Mayo Clinic, 1996-2013

, 2019
Anagha Kumar, Elizabeth K. Blixt, Lisa A. Drage, Rokea A. el‐Azhary, David A. Wetter   +4 more
openalex   +2 more sources

When Autoimmunity Meets Malignancy: A Rare Case of Concomitant Systemic Lupus and Multiple Myeloma

Clinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT The association between systemic lupus erythematosus (SLE) and multiple myeloma (MM) is rare, with fewer than 20 cases reported in the literature, raising questions about the link between chronic immune dysregulation and oncogenesis. We report the case of a 43‐year‐old Malagasy woman in whom a monoclonal β2‐globulin spike, incidentally ...
Solohery Jean Noël Ratsimbazafy, Havantsoa Nomena Fandresena Andrianarisambatra, Rajo Païdia Radinasoa, Hitsy Andraina Razafindrazaka, Tahianasoa Randriamampianina, Rija Mikhaël Miandrisoa, Fidiarivony Ralison, Hanta Marie Danielle Vololontiana   +7 more
wiley   +1 more source

Primary antiphospholipid syndrome complicated by recurrent acute ST-elevation myocardial infarction: a case report. [PDF]

Front Cardiovasc Med
Huo L, Hou C, Cao C, Peng X, Liu J.
europepmc   +1 more source

S-hydroxychloroquine prevents the antiphospholipid thrombogenic complexes for antiphospholipid syndrome treatment

Ming‐Shou Hsieh, Heng-Wei Liu, Fuyou Guo, Dawei Song, Mengyuan Li, Tsu‐Yi Chao, Iat-Hang Fong, Yu‐Sheng Chang, Chi‐Tai Yeh   +8 more
openalex   +1 more source

Clarifying the record on hydroxychloroquine for the treatment of patients hospitalized with COVID-19

, 2020
Eli S. Rosenberg, David R. Holtgräve, Tomoko Udo   +2 more
openalex   +1 more source

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a BTLA Agonist Antibody (Venanprubart) in Healthy Participants, Patients with Systemic Lupus Erythematosus, and Patients with Psoriasis: Results From Three Phase 1 Studies

Clinical Pharmacology in Drug Development, Volume 15, Issue 1, January 2026.
Abstract Venanprubart (LY3361237), an agonist antibody to B and T lymphocyte attenuator (BTLA), was developed as a potential treatment for autoimmune disorders, including systemic lupus erythematosus (SLE) and psoriasis. We tested venanprubart in three human Phase 1 safety studies: a single ascending dose (SAD) study in healthy participants (1/2/5/15 ...
Andrew C. Vendel, Olivier Benichou, Ching‐Yun Chang, Gourab Datta, Andrea Ferrante, Indrajit Ghosh, Brian A. Moser, Susan E. Sweeney, Jennifer Witcher, Matthew D. Linnik   +9 more
wiley   +1 more source

Lupus-Associated Knee Pain: An Atypical Presentation of Systemic Lupus Erythematosus in a Young Male. [PDF]

Cureus
Pessoa AL, Teixeira Reis A, Santos Costa A, Rodrigues M, De Almeida Robalo C.   +4 more
europepmc   +1 more source

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019

, 2020
Bathon, J., Breedveld, F., Burmester, G., Bykerk, V., Crofford, L., Cronstein, B., Dougados, M., Furst, D., Kalden, J., Mariette, X., Mease, P., Melchers, F., Rosenbaum, J., Sieper, J., Smolen, J., Weinblatt, M., Winthrop, K.   +16 more
core   +1 more source

Psychomotor Agitation Following Treatment with Hydroxychloroquine [PDF]

, 2017

core   +1 more source

A novel surface plasmon resonance approach to assess anti‐dsDNA antibody kinetics and disease severity in systemic lupus erythematosus

Clinical &Translational Immunology, Volume 15, Issue 1, 2026.
An innovative FO‐SPR biosensor for anti‐dsDNA kinetic profiles to differentiate SLE patients with or without nephritis. Maximal FO‐SPR binding correlates with disease activity in lupus nephritis. Abstract Objectives Anti‐dsDNA antibodies are established biomarkers in systemic lupus erythematosus (SLE), yet the clinical utility of conventional assays ...
Carole Nagant, Maxime Taghavi, Hasnae Ben Kacem Ziani, Nathalie Ghorra, Valérie Badot, Sarah Parmentier, Francis Corazza   +6 more
wiley   +1 more source